Efavirenz to Nevirapine Switch and Low-Density Lipoprotein (LDL)-Dyslipidemia
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
Dyslipidemia and coronary heart disease (CHD) are increasingly recognized in persons with
human immunodeficiency virus (HIV) infection. Many antiretrovirals, including efavirenz
(EFV), are associated with increases in serum lipids. The investigators investigated whether
stopping EFV and replace EFV by nevirapine can reduce significantly Low-Density Lipoprotein
cholesterol, while keeping virologic control of HIV.